Brief: Xilio Therapeutics Announces Initiation Of Patient Dosing In Phase 1/2 Clinical Trial Of XTX202
20/01/2022 12:32
Jan 20 (Reuters) - Xilio Therapeutics Inc XLO.O :
* XILIO THERAPEUTICS ANNOUNCES INITIATION OF PATIENT DOSING IN PHASE 1/2
CLINICAL
TRIAL OF XTX202 FOR TREATMENT OF PATIENTS WITH SOLID TUMORS
Source text for Eikon: ID:nGNX4ZSNtq
Further company coverage: XLO.O
Recent news on Xilio Therapeutics
See all newsXilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla